CytomX/$CTMX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About CytomX
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
- Ticker
- $CTMX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 69
- Headquarters
- South San Francisco, United States
- Website
- www.cytomx.com
CytomX Metrics
BasicAdvanced
$447M
-
-$0.45
2.24
-
Price and volume
Market cap
$447M
Beta
2.24
52-week high
$8.21
52-week low
$1.87
Average daily volume
4.7M
Financial strength
Current ratio
7.82
Quick ratio
7.697
Long term debt to equity
0.014
Total debt to equity
0.015
Profitability
EBITDA (TTM)
-93.664
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-608.94%
Operating margin (TTM)
-676.41%
Effective tax rate (TTM)
-0.27%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
-22.68%
Return on equity (TTM)
-43.55%
Valuation
Price to revenue (TTM)
28.697
Price to book
1.57
Price to tangible book (TTM)
1.58
Price to free cash flow (TTM)
-7.893
Free cash flow yield (TTM)
-12.67%
Free cash flow per share (TTM)
-0.26
Growth
Revenue change (TTM)
-87.65%
Earnings per share change (TTM)
-289.69%
3-year revenue growth (CAGR)
-47.09%
10-year revenue growth (CAGR)
2.69%
3-year earnings per share growth (CAGR)
46.12%
10-year earnings per share growth (CAGR)
-11.98%
What the Analysts think about CytomX
Analyst ratings (Buy, Hold, Sell) for CytomX stock.
Analyst projections of the future price of CytomX stock.
Bulls say / Bears say
In phase 1 metastatic colorectal cancer cohorts, Varseta-M produced confirmed response rates of 20% at 8.6 mg/kg and 32% at 10 mg/kg, with estimated median progression-free survival of 6.8 and 7.1 months. These are encouraging early signals in a heavily pre-treated population, though they still need confirmation in later-stage trials. (U.S. Securities and Exchange Commission)
CytomX reported $348 million in cash and investments at the end of Q3 2026 and expects its cash runway to extend into the second half of 2028. This gives it time to advance Varseta-M and its other programmes without an immediate funding need. (CytomX Therapeutics, Inc.)
Regeneron selected two additional collaboration targets, triggering a $37 million payment to CytomX, and may select up to six more. The expanded agreement offers potential milestone payments of up to about $4 billion, although these depend on future development and commercial progress. (CytomX Therapeutics, Inc.)
Diarrhoea remains a material safety concern for Varseta-M: the phase 1 report records grade 3 cases across its dose cohorts and serious treatment-related events including diarrhoea, dehydration, acute kidney injury and colitis. This could limit tolerable dosing or complicate use in a broader patient population. (U.S. Securities and Exchange Commission)
The key Varseta-M monotherapy update moved from the end of 2026 to January 2027, while the first potential registrational study is only planned for the first half of 2027. Dose selection and the path to later-stage proof therefore remain unresolved. (CytomX Therapeutics, Inc., CytomX Therapeutics, Inc.)
Competition in colorectal cancer ADCs is advancing: management identified AbbVie and Merck KGaA candidates in phase 3, as well as newer CDH17 ADCs. This could make it harder for Varseta-M to establish a lasting advantage, particularly if its clinical progress slows. (Stock Analysis)
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2026.
CytomX Financial Performance
Revenues and expenses
CytomX Earnings Performance
Company profitability
Upcoming events
No upcoming events
CytomX News
AllArticlesVideos
Funds containing CytomX
Fund name | Fund size | $CTMX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.03% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.01% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
